tradingkey.logo

REFILE-India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact

ReutersJul 10, 2025 2:08 PM

- India's Glenmark Pharmaceuticals GLEN.NS said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie ABBV.N have signed an exclusive global licensing agreement for IGI's cancer treatment, ISB 2001.

Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize ISB 2001 in North America, Europe, Japan and Greater China.

Subject to regulatory approvals, IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in additional milestone payments, according to the agreement.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI